<span item_type="fundamental" item_id="51fe384b9469cdb4df2f38e4f044f070" counter_id="ST/US/ATHA" env="prod"></span><span item_type="announcement" item_id="579899041791282945" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 0.</p><p>EPS: As of FY2025 Q3, the actual value is USD -1.68, missing the estimate of USD -1.22.</p><p></p><h3>Financial Results</h3><h4>Cash Position</h4><ul><li>Cash, cash equivalents, and investments were $25.2 million as of September 30, 2025, compared to $51.3 million as of December 31, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li><li>Net cash used in operations was $26.3 million for the nine months ended September 30, 2025, compared to $71.2 million for the nine months ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li></ul><h4>Research and Development (R&amp;D) Expenses</h4><ul><li>R&amp;D expenses were $2.8 million for the quarter ended September 30, 2025, compared to $17.9 million for the quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li></ul><h4>General and Administrative (G&amp;A) Expenses</h4><ul><li>G&amp;A expenses were $4.1 million for the quarter ended September 30, 2025, compared to $7.6 million for the quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li></ul><h4>Net Loss</h4><ul><li>Net loss was $6.6 million, or $1.68 per share, for the quarter ended September 30, 2025, compared to a net loss of $28.7 million, or $7.46 per share (on a split-adjusted basis), for the quarter ended September 30, 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>Athira Pharma continues to explore strategic alternatives focusing on maximizing stockholder value.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li><li>The company remains encouraged by the promising data supporting the continued development of ATH-1105 as a potential therapy for ALS.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li><li>Athira plans to advance the ATH-1105 program into ALS patients to bring a potential novel therapy to those in need of an effective treatment option.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1620463/000119312525269506/atha-ex99_1.htm"></span></li></ul>

Athira Pharma | 8-K: FY2025 Q3 Revenue: USD 0